I think that's a fair example but it had the wrinkle that an FDA commissioner explicitly changed what the Agency's position on tobacco regulation was [1].

I don't have as much time to offer a similar assessment of the first two 'official' Major Questions Doctrine cases in the Biden administration, but neither was nearly as contentious as the FDA reversing its prior position.

For this reason, I see this decision as an argument against an agency changing course from an accepted previous (but not Congressionally defined) perspective. However, Chevron—at least according to interviews with lawmakers responding to the 'MQD' usage—ran counter to what the supposed understanding of how agency work would function. Again, I can find primary sources later.

1. https://www.nytimes.com/2000/03/22/us/high-court-holds-fda-c...